OrbiMed Advisors LLC disclosed a series of sales of Sionna Therapeutics Inc common stock executed over three consecutive trading days in mid-April 2026. The firm disposed of 510,783 shares in total, with transaction prices spanning $44.51 to $45.34 per share and cumulative proceeds of $22,945,043.
Transaction details are as follows:
- April 14, 2026 - sale of 47,814 shares at $44.51 per share.
- April 15, 2026 - sale of 235,863 shares at $44.64 per share.
- April 16, 2026 - sale of 226,906 shares at $45.34 per share.
The filing indicates that, following these dispositions, OrbiMed Advisors now indirectly holds 3,020,119 shares of Sionna Therapeutics. Those holdings are attributed to OrbiMed Private Investments VIII, LP, for which OrbiMed Capital GP VIII LLC is the general partner and OrbiMed Advisors LLC serves as the managing member. The sales were carried out pursuant to a pre-arranged 10b5-1 trading plan.
Investor attention to Sionna has coincided with analyst activity. Guggenheim raised its price target on Sionna to $50 while maintaining a Buy rating, signaling confidence in the company’s financial position. Separately, Citizens initiated coverage with a Market Outperform rating and set a $63 price target; that target was derived using a risk-adjusted, discounted cash flow model by analyst Jonathan Wolleben at Citizens.
On the company’s reported financials, Sionna Therapeutics closed fiscal year 2025 with $310.3 million in cash and projects that this balance provides a runway through 2028. The company is also advancing clinical development, most notably with the Phase IIa preciSION study aimed at improving outcomes for patients with cystic fibrosis.
The disclosed stock sales, the firm’s remaining indirect stake, the 10b5-1 plan, analyst recommendations and targets, the stated cash position, and the ongoing Phase IIa study are the elements reported in filings and analyst notes referenced within the disclosures.
Summary of disclosures contained in filings:
- 510,783 Sionna Therapeutics shares sold by OrbiMed Advisors LLC between April 14-16, 2026.
- Total proceeds from the transactions: $22,945,043.
- Post-transaction indirect holdings: 3,020,119 shares held by OrbiMed Private Investments VIII, LP.
- Sales executed under a pre-arranged 10b5-1 plan.
- Analyst activity: Guggenheim - Buy, $50 target; Citizens - Market Outperform, $63 target via risk-adjusted DCF by Jonathan Wolleben.
- Fiscal year 2025 cash balance: $310.3 million; projected cash runway to 2028.
- Ongoing Phase IIa preciSION study focused on cystic fibrosis outcomes.